Pre-made Sutimlimab benchmark antibody ( Whole mAb, anti-C1S therapeutic antibody, Anti-EDSPD2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Sutimlimab biosimilar, Whole mAb, Anti-C1S Antibody: Anti-EDSPD2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sutimlimab (INN; development code BIVV009) is a monoclonal antibody that is being investigated for cold agglutinin disease.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-537-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Sutimlimab biosimilar, Whole mAb, Anti-C1S Antibody: Anti-EDSPD2 therapeutic antibody
INN Name	Sutimlimab
Target	C1S
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Bioverativ;True North Therapeutics
Conditions Approved	na
Conditions Active	Autoimmune haemolytic anaemia;Idiopathic thrombocytopenic purpura
Conditions Discontinued	Bullous pemphigoid;Renal transplant rejection
Development Tech	na